

# **FACSIMILE**

RECEIVED
CENTRAL FAX CENTER

FEB 2 3 2005

### NOTICE OF CONFIDENTIALITY

This transmission is intended only for the use of the Addressee and may contain information that is: 1. Subject to attorney/client privilege; 2. Attorney work product; or 3. Confidential. If you are not the intended recipient, you are hereby notified that any dissemination, distribution or copying of the information contained in this facsimile is strictly unauthorized and prohibited. If you have received this facsimile in error, please notify us immediately by collect telephone to the sender named below.

DATE: February 23, 2005

TO: Examiner E. Huang

NUMBER OF PAGES: 13 (including cover)

FAX NO: (703) 872-9306

FROM: Frank W. Forman

PFIZER INC.

U.S. Appln. No. 10/667,182 Our reference: PC25302A PATENT DEPARTMENT EASTERN POINT ROAD GROTON, CT 06340

(860) 715-5669

FACSIMILE NO.: (860) 441-5221

FACSIMILE UNIT: PITNEY BOWES 2050

### To follow are:

1) Amendment transmittal (2 copies);

2) Amendment Under 37 C.F.R. § 1.116.

Frank W. Forman

FWF/kds

cc: recordable

## Patent Application Attorney Docket No.PC25302A

CERTIFICATE OF TRANSMISSION: The undersigned hereby certifies that this correspondence, and all papers filed herewith, is being filed via facsimile transmission to fax phone number (703) 872-9308 on February 23, 2005.  By								RECEIVED ENTRAL FAX CENTE	R
		/— (S	ignature of person fa Kelley D. Surprena					FEB 2 3 2005	
		(Туре	ed or printed name o	f pers	on)				
				DT	RADEN	MARK OFFICE	<u>.</u>		
IN RE APPLICA	ATION OF:	Y. Katsu	et al.		:			_	
APPLICATION NO.: 10/667,182 : Examiner: E. Huang									
FILING DATE: 17 September 2003 : Group Art Unit: 1625							S25		
Commissioner f Mail Stop AF P.O. Box 1450 Alexandria, VA	or Patents	HT4 Recep	dazopyridine otor Modulato	rs	•				
Sir:	A	AMENDME	NT TRANSM	11 <b>T</b> T	AL				
Transmitted her	ewith is an	amendme	nt in the abov	e-id	entified	application.			
The fee has bee	n calculate	d as show	n below.						
			IS AS AMEN	DE	)				
	(2) Claims Remaining After mendment	(3 <sup>'</sup> )	(4) Highest Number Previously Paid For		(5) resent Extra	(6)	Additior Fee	nal	
Total Claims	20*	minus	27**	=	0	X \$50.00	0.00		
Independent Claims	3*	minus	3***	=	0	X \$200.00	0.00		
Multiple Dependent Claim(s) fee						\$300.00	0.00		
** If the *** If the	"Highest No "Highest No	o. Previous o. Previous	ly Paid for is ly Paid for is	les les	s than 2 s than 3	mn 4, write "0" 20, write "20" ir 3, write "3" in th a one (1) mon	n this space.	ce.	

# Best Available Copy

Patent Application
Attorney Docket No.PC25302A

the response date is also enclosed. Authorization to charge the fee transfer is made separately therein.
No additional fee is required.
Please charge Deposit Account No. 16-1445 in the amount of \$ Two copies of this paper are enclosed.
The Commissioner is hereby authorized to charge any additional fees, which may be required under 37 C.F.R. §§1.16 and 1.17, or credit any overpayment, to Deposit Account No. 16-1445. Two copies of this paper are enclosed.

Date: 23 Feb05

Respectfully submitted,

Frank W. Forman Attorney for Applicant(s)

Reg. No. 42,547

Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5669

Patent Application Atty. Docket No. 25302A

Group Art Unit: 1625

CERTIFICATE OF TRANSMISSION: The undersigned herebycertifies that this correspondence, and all papers file is being filed via facsimile transmission to fax phone number (703) 872-9306 on 23 February 2005.  By  (Signature of person faxing)  Kelley D. Surprenant	d herewith,
(Typed or printed name of person)	RECEIVED
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE IN RE APPLICATION OF: Y. Katsu et al. :	FEB 2 3 2005
	•

APPLICATION NO.: 10/667,182 : Examiner: E.M. Huang

TITLE: N-Substituted Piperidinyl-Imidazopyridine :
Compounds As 5-HT4 Receptor Modulators

17 September 2003

Mail Stop AF Hon. Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

FILING DATE:

### AMENDMENT UNDER 37 C.F.R. § 1.116

In response to the final Office Action mailed 23 December 2004, entry of the present Amendment, and reconsideration and withdrawal of the rejections are respectfully requested. Inasmuch as this Amendment is being submitted within the three-month shortened statutory period set in the Office Action to expire on 23 March 2005, Applicants respectfully submit that no extension of time should be necessary. If the Commissioner determines that an extension of time and/or a fee is necessary, the same is hereby requested and the Commissioner is authorized to charge any necessary fees to maintain the pendency of this application to deposit account No. 16-1445.

Claim amendments begin on page 2.

Remarks begin on page 6.